Meeting
2016 ASCO Annual Meeting
Prognosis of triple negative breast cancer patients who attain pathological complete response with neoadjuvant carboplatin/docetaxel and do not receive adjuvant anthracycline chemotherapy.
Authors
Priyanka Sharma
University of Kansas Medical Center, Westwood, KS
Priyanka Sharma , Bruce F. Kimler , Claire Ward , Anne O'Dea , Marc Steven Hoffmann , Jennifer R. Klemp , Marilee McGinness , Jamie Lynn Wagner , Joshua Mammen , Amanda Leigh Amin , Carolyn Lehn , Roy A. Jensen , Andrew K. Godwin , Qamar J. Khan
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Breast Cancer—Triple-Negative/Cytotoxics/Local Therapy
Track
Breast Cancer
Sub Track
Triple-Negative Breast Cancer
Citation
J Clin Oncol 34, 2016 (suppl; abstr 1015)
DOI
10.1200/JCO.2016.34.15_suppl.1015
Abstract #
1015
Poster Bd #
120
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Neoadjuvant cemiplimab with platinum-doublet chemotherapy and cetuximab to de-escalate surgery and omit adjuvant radiation in locoregionally advanced head & neck squamous cell carcinoma (HNSCC).
First Author: Winston Wong
Poster
2020 ASCO Virtual Scientific Program
Neoadjuvant docetaxel + carboplatin versus epirubicin+cyclophosphamide followed by docetaxel in triple-negative, early-stage breast cancer (NeoCART): Results from a multicenter, randomized controlled, open-label, phase II trial.
First Author: Liulu Zhang
Poster
2014 ASCO Annual Meeting
Efficacy of neoadjuvant carboplatin/docetaxel chemotherapy in sporadic and BRCA-associated triple-negative breast cancer (TNBC).
First Author: Priyanka Sharma
Poster
2014 ASCO Annual Meeting
Differential response of neoadjuvant chemotherapy with taxane-carboplatin versus taxane-epirubicin in patients with locally advanced triple-negative breast cancer.
First Author: Jiayu Wang